LANDOUZY DEJERINE DYSTROPHY

Clinical trials for LANDOUZY DEJERINE DYSTROPHY explained in plain language.

Never miss a new study

Get alerted when new LANDOUZY DEJERINE DYSTROPHY trials appear

Sign up with your email to follow new studies for LANDOUZY DEJERINE DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Breakthrough drug trial offers hope for rare muscle disease

Disease control Recruiting now

This study is testing an experimental drug called AOC 1020 for people with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 participants will receive either the drug or a placebo via IV infusion every six weeks …

Matched conditions: LANDOUZY DEJERINE DYSTROPHY

Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

LANDOUZY DEJERINE DYSTROPHY

Get alerted when new LANDOUZY DEJERINE DYSTROPHY trials appear

Breakthrough drug trial offers hope for rare muscle disease